Azilsartan mopivabil

• CAT Number: I045119
• CAS Number: 2271428-31-8
• Molecular Formula: C38H36N4O8
• Molecular Weight: 676.71
• Purity: ≥95%
• Synonyms: [4-(2,2-dimethylpropanoyloxy)-3-methoxyphenyl]methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
• InChI: InChI=1S/C38H36N4O8/c1-6-47-36-39-29-13-9-12-28(34(43)48-22-24-16-19-30(31(20-24)46-5)49-35(44)38(2,3)4)32(29)42(36)21-23-14-17-25(18-15-23)26-10-7-8-11-27(26)33-40-37(45)50-41-33/h7-20H,6,21-22H2,1-5H3,(H,40,41,45)
• InChIKey: UIGUEOKVFZHFSB-UHFFFAOYSA-N
• SMILES: CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=CC(=C(C=C6)OC(=O)C(C)(C)C)OC

Azilsartan mopivabil（Cat No.:I045119）is an investigational combination therapy pairing azilsartan, an angiotensin II receptor blocker (ARB), with mopivabil, a long-acting IL-4 receptor alpha antagonist. This dual-action approach is designed to address both cardiovascular and inflammatory pathways, offering potential therapeutic benefit in patients with comorbid hypertension and inflammatory conditions such as asthma or atopic dermatitis. Azilsartan lowers blood pressure by inhibiting vasoconstrictive effects of angiotensin II, while mopivabil targets type 2 inflammation via IL-4/IL-13 signaling blockade. Supplied for research into multi-target therapies in cardio-inflammatory and immune-mediated diseases.